A Single-Center, Open-Label, Randomized, Two-Stage, Two-Way Crossover Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Rifampin Capsules in Healthy Subjects.
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2019
At a glance
- Drugs HSK 3486 (Primary) ; Rifampicin
- Indications Anaesthesia
- Focus Pharmacokinetics
- Sponsors Sichuan Haisco Pharmaceutical
- 09 Jan 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Apr 2019.
- 09 Jan 2019 Planned initiation date changed from 15 Dec 2018 to 30 Jan 2019.
- 06 Dec 2018 New trial record